drugset / Trial / NCT02805153

PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy

NCT02805153

Phase 4 Completed 215 enrolled CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the efficacy and safety of PEG-rhG-CSF in patients with breast cancer receiving chemotherapy

Timeline

Start
2013-04
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegfilgrastim Protein / enzyme biologic 100 ug/kg Subcutaneous
Comparator filgrastim Protein / enzyme biologic 5 ug/kg Subcutaneous

Indications